Dual Agonist 50mg Pen (GIP / GLP-1) – Viogen Pharmaceuticals

Dual Agonist 50mg Pen (GIP / GLP-1) – Viogen Pharmaceuticals

This is a dual GIP and GLP-1 receptor agonist – a receptor-pharmacology class also represented among approved weight-management and type 2 diabetes medicines. It is among the most extensively evidenced weight-management injectable mechanisms currently available, with Phase 3 outcomes in both type 2 diabetes and obesity. This Viogen Pharmaceuticals presentation supplies 50mg in a pre-filled, dial-a-dose pen with 20 needles included, so there is no vial, no reconstitution and no drawing up.

Note on source: this is a generic Viogen-manufactured dual agonist, not a branded medicine. This receptor mechanism is licensed for use in the UK; this particular product is not an MHRA-authorised medicinal product and carries no marketing authorisation. It is supplied as a research compound.

Mechanism of Action

This compound engages two incretin receptors rather than one:

• GLP-1 receptor – slows gastric emptying, promotes satiety, reduces food intake and improves glucose-dependent insulin secretion
• GIP receptor – improves insulin sensitivity and adipose tissue handling of nutrients, and appears to reduce the nausea burden that GLP-1 agonism causes on its own

The second receptor is why this dual-agonist mechanism outperformed GLP-1-only agonists head-to-head in published trial data, while remaining tolerable at higher effective doses.

Clinical Data

• Published 72-week Phase 3 obesity data: mean weight reduction of approximately 20.9% at the 15mg weekly dose, versus approximately 3.1% on placebo
• Published Phase 3 type 2 diabetes programme data: HbA1c reductions of roughly 2.0–2.4 percentage points, exceeding comparator agents
• Published head-to-head data: superior weight reduction versus a GLP-1-only agonist in a direct comparison
• This receptor mechanism is approved by regulators, including the UK's MHRA and the US FDA, under separate branded medicines for type 2 diabetes and, separately, for weight management

Dosage and Titration

This compound has a half-life of around five days, supporting once-weekly subcutaneous administration on the same day each week. The licensed titration schedule for this receptor mechanism exists to manage gastrointestinal tolerance and should be followed:

• Weeks 1–4: 2.5mg once weekly (initiation dose – not intended to produce weight loss)
• Weeks 5–8: 5mg once weekly
• Weeks 9–12: 7.5mg once weekly
• Weeks 13–16: 10mg once weekly
• Weeks 17–20: 12.5mg once weekly
• Each step up should only be taken if the previous dose is well tolerated; staying at a lower effective dose is entirely reasonable

This pen dials 2.5mg, 5mg, 7.5mg, 10mg and 12.5mg. The 15mg maintenance dose used in the headline Phase 3 obesity data is not a single-click option on this device.

Administration

• Route: subcutaneous only – abdomen, thigh or upper arm. Never intramuscular or intravenous
• Rotate the injection site each week
• Attach a fresh 31g needle for every dose; 20 are supplied
• Prime the pen before first use as described in the enclosed leaflet
• A missed dose can be taken within 4 days; beyond that, skip it and resume the usual schedule
• The dosing day can be changed provided at least 3 days separate two injections

Side Effects

The adverse-event profile is dominated by gastrointestinal effects, dose-dependent and typically worst in the first days after a dose increase:

• Very common: nausea, diarrhoea, reduced appetite, vomiting, constipation
• Common: dyspepsia, abdominal pain, fatigue, injection-site reactions, hair thinning secondary to rapid weight loss
• Serious but uncommon: pancreatitis, gallbladder disease including cholelithiasis, severe dehydration and consequent renal injury
• Thyroid C-cell tumours occurred in rodents; human relevance is unestablished but the class warning stands

Practical mitigation: eat smaller meals, prioritise protein, avoid high-fat meals near injection day, and maintain fluid and electrolyte intake. Resistance training and adequate protein are what protect lean mass during a large deficit.

Who Should Not Use It

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• History of pancreatitis
• Pregnancy, planned pregnancy or breastfeeding
• Type 1 diabetes; or type 2 diabetes on insulin or sulfonylureas without dose adjustment and medical supervision
• Severe gastrointestinal disease including gastroparesis
• Note: this compound may reduce the effectiveness of oral contraceptives around initiation and dose increases – a barrier method is advised for 4 weeks after each

Storage

• Store unopened at 2–8°C in a refrigerator. Do not freeze
• Keep in the outer carton to protect from light
• Once in use, the pen may be kept at room temperature below 30°C for a limited period as stated in the leaflet
• Do not use if the solution is cloudy, discoloured or contains particles

Pack Contents

• 1 x pre-filled Viogen dual agonist pen, 50mg/3mL cartridge
• 20 x 31g 5mm disposable pen needles
• 1 x instruction leaflet
• Verification code inside the carton for authentication against the manufacturer's system

Frequently Asked Questions

How long will a 50mg pen last?
It depends on the dose. At 2.5mg weekly it covers 20 doses; at 5mg, 10 doses; at 12.5mg, four doses. The cartridge holds 50mg in total.

Dual agonist or triple agonist?
This GIP/GLP-1 dual agonist has Phase 3 evidence and regulatory approval behind its mechanism. Newer triple GLP-1/GIP/glucagon agonists showed larger reductions in Phase 2 data but remain investigational. The dual-agonist mechanism is the better-evidenced choice; the triple-agonist mechanism is the more aggressive one.

Can I use it alongside a steroid cycle?
There is no direct pharmacological conflict, but the appetite suppression works against a bulking phase and the GI effects can make high-calorie eating difficult. It is far better suited to a cutting phase or an off-cycle period.

Do I need to reconstitute anything?
No. The pen is pre-filled. Attach a needle, dial the dose, inject.

Will the weight come back if I stop?
In published withdrawal-study data for this receptor mechanism, participants who stopped regained a substantial proportion of the weight lost. Treat the compound as a tool that buys time to build habits, not as the habit itself.